zoloft-ssri-lawyer-possible-zoloft-side-effects-and-birth-defects-infographic

ZOLOFT Possible Zoloft Birth Defects: Common Side Effects: Abdominal Birth Defects Autism Drowsiness Cleft Lip or Palate Blindness Nausea Down's Syndrome Clubfoot Allergic Reactions causing Swelling Hypoplastic Left/Right Heart Syndrome Hernia Decreased Sex Drive Persistent Pulmonary Hypertension (PPHN) Spina Bifida Serious Side Effects: Septal Heart Defects (atrial or ventricular) Other Birth Defects Heart Disease Zoloft (sertraline hydrochloride) is a selective serotonin reuptake Serotonin Syndrome inhibitor (SSRI) antidepressant used to treat conditions like anxiety Birth Defects disorders, major depressive disorder, and obsessive-compulsive disorder. SSRIS work by increasing serotonin levels which boosts the brain's ability to send and receive signals, and in turn positively affects mood. In 1991, TIMELINE Increased Risk of Suicidal Behavior 1991-2012 the FDA approved Zoloft for sale on the market by its manufacturer, Pfizer. Zoloft was one of the first antidepressants introduced and has In 2011, Zoloft was the third FDA laBeLs earned Pfizer great sales numbers. 2012: A study found that the fetuses of pregnant warNING LABELS bestselling psychiatric drug with over 37 million prescriptions. woman who used SSRIS had slower head growth and were twice as likely to be born preterm. 2X'S aS LIKELY 2004: The FDA required all antidepressant manufacturers to include warnings about an increased risk of suicidal behavior in children and teenagers taking antidepressants. 2006: The FDA ordered antidepressants like Zoloft to include warnings about an 2012: Zoloft birth defect increased risk of PPHN in newborns. This lawsuits were consolidated label change was based on a medical study through the multidistrict which found that mothers who took SSRIS litigation process. during pregnancy were 6 times more likely to give birth to a newborn with PPHN. BITH DEFECT LawsUITS CALL d'OLIVeira & associates af 1-800-992-6878 For a Free CONSULTATION 2007: The FDA expanded antidepressant suicide warnings to include young adults up to the age of 24 in the group of patients who face an increased risk of suicidal behavior. CONSOLIDATED seroTONIN LEVELS INCrease